Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review. | ClinicLens
Chimeric antigen receptor T-cell (CAR-T) therapy is an established treatment for several hematological malignancies, with peripheral blood mononuclear cells (PBMCs) serving as the starting material for manufacturing. Cryopreservation of PBMCs may offer logistical flexibility, alt
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.